News
News Release
Cyclomedical Applications Group
Expands its International Reach
Contact: James F. Lamb, Ph.D.
+1-865-670-9021
jlamb@cyclomedical.com
KNOXVILLE, Tennessee,
2011 October 15—Cyclomedical Applications Group has expanded its international presence with the appointment of its latest new Associate.
Mr. Nicola Ceccomancini has more than ten years of experience in radiopharmaceutical production, facility GMP operations and organizational development. During his past tenure at GE Healthcare, IBA Molecular Italy and SWAN Isotopen AG, he was responsible for the installation, start-up, operation, maintenance, and improvement of four cyclotrons and related GMP aseptic manufacturing facilities and fully validated quality control laboratories. He has remarkable experience in Regulatory Affairs and EHS. Nick Ceccomancini holds a M.Sc. in Chemistry & Pharmaceutical Technologies from the University of Chieti, Italy. His operational base is in Scafa, Pescara, Italy.
Mr. David Drummond, Vice-President of International Marketing for Cyclomedical stated, “We are continuing to expand our operations outside of the United States, and Nick, with his location in Europe, is a welcome addition to our team of experts. He is well situated to support our assignments in Europe and the Middle East.” Dr. James Lamb, President of Cyclomedical, added, “Nick Ceccomancini has superb credentials in the areas of expertise in which Cyclomedical excels. We are looking forward to working with him.”
Cyclomedical Applications Group is an organization of experienced radiopharmaceutical experts serving the radiopharmaceutical industry, especially owners and operators of medical cyclotrons dedicated to the production of positron emitting radioisotopes. It works primarily with facilities producing and distributing F-18 FDG–the most widely used positron-emitting radiopharmaceutical in PET scanning.
Consulting services offered by the company range from short-term consultation to longer-term retainer arrangements and assistance with regulatory agencies as well as cyclotron operation and FDG production problems. Contract management services range from full responsibility for a cyclotron/FDG production facility to a monitoring posture in support of an in-place management team. The Associates are a group of experts who can offer services and capabilities to clients who operate PET accelerators.
The goal of Cyclomedical is to provide a full range of support expertise including FDG market research and development, facility financing, facility planning and operation, licensing and safety, and FDA regulatory issues. The company currently has operational responsibility for several cyclotron/FDG facilities and is providing cyclotron consultation services to a number of cyclotron operating companies. Company headquarters are located in the United States and in the United Arab Emirates. For more information, see the Cyclomedical web site at www.cyclomedical.com.